Burney Co. Sells 53,857 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Burney Co. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 89.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,529 shares of the medical equipment provider’s stock after selling 53,857 shares during the period. Burney Co.’s holdings in Lantheus were worth $584,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LNTH. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after buying an additional 257,022 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after acquiring an additional 796,000 shares during the period. Geode Capital Management LLC boosted its stake in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Reinhart Partners LLC. grew its holdings in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 0.1 %

LNTH stock opened at $91.47 on Friday. The firm has a market capitalization of $6.36 billion, a PE ratio of 15.22 and a beta of 0.46. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The stock’s 50 day moving average is $89.72 and its 200-day moving average is $99.85.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.